Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia

(2015) Rosemary E. Gale et al.   JOURNAL OF CLINICAL ONCOLOGY

The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies

(2013) Masamitsu Yanada et al.   CANCER

High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial

(2013) Markus Schaich et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

(2013) Jie Jin et al.   LANCET ONCOLOGY

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

(2011) J.-H. Lee et al.   BLOOD

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

(2010) S. Ohtake et al.   BLOOD

Prognostic Significance ofCEBPAMutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of DoubleCEBPAMutations and the Interaction WithFLT3andNPM1Mutations

(2010) Claire L. Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE